Medicamen Biotech Ltd

Medicamen Biotech Ltd

₹ 415 -0.71%
18 Apr - close price
About

Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.[1]

Key Points

Product Offerings
The Company manufactures formulations for anti-retroviral, oncology, cardiovascular, diabetic and hypertension, nutraceutical, and other products. Its key products are Efavirenz, Tenofovir (TDF), Gemcitabine, and Finished Dosage Forms (FDF) of these Products and Bio-Technology. [1]

  • Market Cap 524 Cr.
  • Current Price 415
  • High / Low 904 / 355
  • Stock P/E 36.8
  • Book Value 159
  • Dividend Yield 0.24 %
  • ROCE 10.6 %
  • ROE 8.78 %
  • Face Value 10.0

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 2.61 times its book value
  • The company has delivered a poor sales growth of 4.34% over past five years.
  • Company has a low return on equity of 9.63% over last 3 years.
  • Dividend payout has been low at 8.80% of profits over last 3 years
  • Company has high debtors of 159 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
32.92 20.34 27.53 32.52 32.64 22.75 33.09 33.53 34.12 37.15 40.50 42.67 44.20
27.66 15.46 21.49 26.30 26.34 17.78 27.43 27.67 28.26 30.38 33.09 36.51 38.61
Operating Profit 5.26 4.88 6.04 6.22 6.30 4.97 5.66 5.86 5.86 6.77 7.41 6.16 5.59
OPM % 15.98% 23.99% 21.94% 19.13% 19.30% 21.85% 17.10% 17.48% 17.17% 18.22% 18.30% 14.44% 12.65%
-0.00 0.54 0.08 0.48 0.83 0.34 0.96 0.52 0.63 0.35 0.38 0.55 0.83
Interest 0.09 0.36 0.04 0.30 0.49 0.56 0.77 0.62 0.68 0.86 0.96 0.91 0.65
Depreciation 0.71 0.41 1.33 1.35 1.57 1.52 1.53 1.62 1.60 1.61 1.68 1.80 1.76
Profit before tax 4.46 4.65 4.75 5.05 5.07 3.23 4.32 4.14 4.21 4.65 5.15 4.00 4.01
Tax % 32.29% 10.75% 12.42% 16.44% 25.64% 14.55% 17.13% 13.04% 10.69% 13.12% 14.37% 24.75% 31.17%
3.01 4.14 4.15 4.22 3.78 2.75 3.59 3.61 3.76 4.05 4.42 3.01 2.77
EPS in Rs 2.46 3.39 3.40 3.45 3.09 2.25 2.94 2.85 2.97 3.20 3.49 2.38 2.19
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
101 64 73 78 67 82 112 123 117 110 115 138 165
98 64 68 73 62 71 95 105 99 90 91 113 139
Operating Profit 3 -0 5 5 6 12 17 17 18 20 24 25 26
OPM % 3% -0% 7% 6% 8% 14% 15% 14% 15% 18% 21% 18% 16%
1 1 1 1 1 0 2 4 2 1 2 2 2
Interest 3 4 4 4 4 4 3 1 1 2 2 3 3
Depreciation 2 2 2 2 2 2 2 2 2 3 6 6 7
Profit before tax -1 -5 0 0 1 6 14 18 17 17 18 17 18
Tax % -28% -1% 44% -267% 32% 19% 27% 31% 26% 25% 18% 13%
-1 -5 0 0 0 5 10 12 12 12 15 15 14
EPS in Rs -1.01 -5.81 0.10 0.46 0.48 4.91 8.89 10.28 10.04 10.22 12.20 11.86 11.26
Dividend Payout % -0% -0% -0% -0% -0% -0% 12% 10% 5% 10% 8% 8%
Compounded Sales Growth
10 Years: 8%
5 Years: 4%
3 Years: 6%
TTM: 33%
Compounded Profit Growth
10 Years: 18%
5 Years: 8%
3 Years: 7%
TTM: 4%
Stock Price CAGR
10 Years: 46%
5 Years: -4%
3 Years: -7%
1 Year: -44%
Return on Equity
10 Years: 11%
5 Years: 11%
3 Years: 10%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 8 8 9 10 10 11 12 12 12 12 12 13 13
Reserves 11 7 7 7 8 15 63 75 110 122 136 181 189
14 17 15 21 19 18 14 12 11 19 26 26 29
35 33 33 31 23 30 28 38 43 39 52 57 66
Total Liabilities 69 65 65 69 60 73 118 137 176 192 226 277 296
23 23 22 20 19 19 25 24 34 90 92 92 92
CWIP 0 0 1 -0 -0 0 0 15 40 -0 -0 -0 -0
Investments 0 0 0 0 0 0 0 -0 2 2 2 4 6
46 42 42 49 41 54 92 97 100 101 131 180 198
Total Assets 69 65 65 69 60 73 118 137 176 192 226 277 296

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-3 -2 5 -3 6 4 -5 4 12 13 5 -4
-1 -1 -1 0 -1 -2 -8 -15 -39 -18 -8 -8
3 2 -4 3 -5 -1 33 -4 21 6 4 28
Net Cash Flow -2 -1 1 -0 0 0 20 -14 -6 1 1 17

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 86 105 102 124 87 114 126 129 137 165 193 159
Inventory Days 63 122 95 95 95 102 77 67 85 28 188 230
Days Payable 158 225 209 187 160 165 118 134 160 161 291 232
Cash Conversion Cycle -10 1 -13 32 22 51 85 62 62 32 91 157
Working Capital Days 29 50 44 80 83 96 135 151 162 166 207 213
ROCE % 6% -3% 13% 12% 12% 25% 25% 20% 15% 13% 12% 11%

Shareholding Pattern

Numbers in percentages

10 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
44.83% 44.83% 43.60% 43.60% 43.60% 43.21% 43.21% 43.21% 43.21% 43.21% 43.21% 43.21%
0.41% 0.35% 0.35% 0.40% 0.35% 1.83% 0.17% 0.19% 0.16% 0.22% 0.22% 0.12%
0.00% 0.00% 0.00% 0.00% 0.00% 0.13% 0.20% 0.20% 0.20% 0.20% 0.67% 0.99%
54.75% 54.82% 56.06% 56.01% 56.06% 54.84% 56.42% 56.40% 56.44% 56.38% 55.90% 55.69%
No. of Shareholders 5,2635,5959,1409,3009,1078,3328,2738,2338,2729,41910,25210,639

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents